RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
The LancetPublished 1 January 2003
Naoyuki Nakao, Ashio Yoshimura, Hiroyuki Morita, Masyuki Takada, Tsuguo Kayano, Terukuni Ideura
Citations977
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive nondi diabetic renal disease need to be researched.
Abstract
Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy. However, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive non-diabetic renal disease need to be researched.
Keywords
Medicine
Annals of Internal MedicineA More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
15,131 Citations1999Andrew S. Levey, Juan Bosch +5 more
The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
New England Journal of MedicineThe Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
5,377 Citations1993Edmund J. Lewis, Lawrence G. Hunsicker +2 more
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
New England Journal of MedicineEffect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency
1,765 Citations1996Giuseppe Maschio, Daniele Alberti +7 more
A study to determine the effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases.
Annals of Internal MedicineAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
1,093 Citations2001Tazeen H. Jafar, Christopher H. Schmid +18 more
Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease and is greater in patients with proteinuria.
Journal of Clinical InvestigationTherapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
1,077 Citations1986Sharon Anderson, Helmut G. Rennke +1 more
Control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass, and failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomersular lesions comparable to those seen in untreated group 4 rats.
BMJRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
1,039 Citations2000C. E. Mogensen, Steen Neldam +5 more
Cadesartan 16 mg once daily is as effective as lisinopril 20 mgonce daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes and combination treatment is well tolerated and more effective in reducingBlood pressure.
The LancetRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
897 Citations1999Piero Ruggenenti, Annalisa Perna +7 more
In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria, and the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been instratum 2.
The LancetRenal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
571 Citations1998Piero Ruggenenti, Annalisa Perna +4 more
In patients with chronic nephropathy and high risk of rapid progression to ESRF, ramipril reversed the tendency of GFR to decline with time and a treatment period of sufficient duration eliminated the need for dialysis.
The LancetProgression, remission, regression of chronic renal diseases
549 Citations2001Piero Ruggenenti, Arrigo Schieppati +1 more
Annals of Internal MedicineEffect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease
429 Citations1997Ioannis Giatras, Joseph Lau +1 more
Neither the magnitude of the beneficial effect nor the safety of ACE inhibition was established conclusively, and it remains uncertain whether ACE inhibitors are preferable to other antihypertensive agents in the treatment of nondiabetic renal disease.
Kidney InternationalLong-term comparison between captopril and nifedipine in the progression of renal insufficiency
272 Citations1992P Zucchelli, A Zuccalà +6 more
Comparison of the effects of an ACE inhibitor and a calcium antagonist on both hypertension and the progression of non-diabetic renal insufficiency in a long-term study found blood pressure control was significantly better after randomization.
American Journal of Kidney DiseasesAdditive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
245 Citations1999Domenico Russo, Antonio Pisani +5 more
This study provides first-time evidence that the combination of CEI and LOS in normotensive patients with IgA nephropathy produces a more profound decrease in proteinuria than either drug.
HypertensionA Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared With Enalapril Maleate in Patients With Essential Hypertension
226 Citations1995Alan H. Gradman, Karen E. Arcuri +5 more
Compared with mean changes in supine diastolic pressure in the placebo group, losartan potassium 50 to 150 mg and enalapril maleate 20 mg produced clinically important and statistically significant reductions in blood pressure.
American Journal of Kidney DiseasesEffect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials
203 Citations2000Abhijit V. Kshirsagar, Melanie S. Joy +3 more
Treatment of individuals with chronic renal insufficiency with ACE inhibitors delays the progression of disease compared with placebo across a spectrum of disease causes and renal dysfunction.
Journal of HypertensionSafety of the combination of valsartan and benazepril in patients with chronic renal disease
180 Citations2000Luís M. Ruilope, Jean‐Claude Aldigier +4 more
Investigation of the safety and tolerability of the combination of valsartan and benazepril indicates that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotsin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure.
Nephrology Dialysis TransplantationProteinuria and blood pressure as causal components of progression to end-stage renal failure
178 Citations1996Francesco Locatelli, Daniele Marcelli +6 more
Only primary renal disease and proteinuria were related to renal survival, being baseline plasma creatinine confounding factor, and by blocking the possible causal role of proteinuria and hypertension, end-stage renal failure could be prevented in a significant percentage of patients.
Kidney InternationalAdd-on angiotensin receptor blockade with maximized ACE inhibition
130 Citations2001Rajiv Agarwal
Improvement of GFR and fall in plasma renin activity suggest that renal hemodynamic and endocrine changes are more sensitive measures of AT1 receptor blockade.
American Journal of NephrologyCombination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy
105 Citations1999Lee A. Hebert, Michael E. Falkenhain +3 more
It is concluded that in patients with diabetic nephropathy addition of AT1a therapy to ACEi therapy attenuates AngII effects better thanACEi therapy alone, and it is suggested that combination therapy for the management of diabetic glomerulosclerosis merits further investigation.
HypertensionEfficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment
89 Citations1998Robert D. Toto, Pamela J. Shultz +6 more
It is concluded that once-dailyLosartan, given as monotherapy at doses of 50 or 100 mg or in combination with other antihypertensive drugs, was effective in reducing blood pressure in hypertensive patients with chronic renal disease and that losartan regimens were well tolerated in all groups, including those on hemodialysis.
Journal of Cardiovascular PharmacologyAngiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial
76 Citations1999Giuseppe Maschio, D. Alberti +7 more
Benazepril is effective in slowing the rate of progression and improving the survival of renal function in patients with renal diseases of various origins, and is associated with a clinically relevant decrease in both blood pressure and proteinuria.
American Journal of Kidney DiseasesLate escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease
70 Citations2001Tatsuo Shiigai, Masayoshi Shichiri
Although ACE inhibitors reduce the severity of proteinuria in patients with nondiabetic renal disease, the results show that a proportion of patients escape the antiproteinuric effect and subsequently develop an exacerbation of renal dysfunction.
PubMedLong-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
44 Citations1997Francesco Locatelli, Carbarns Ir +8 more
Data from the extension study clearly demonstrate a long-term beneficial effect in patients randomized to take benazepril during the core study, but because treatment during the extension period was not randomized, the results of this intention-to-treat analysis need to be interpreted with care.
Nihon Toseki Igakkai ZasshiAn overview of regular dialysis treatment in Japan (as of Dec. 31, 1994).
37 Citations1996Kenji Maeda
Nephrology Dialysis TransplantationAntiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease
33 Citations1999M.H. Hemmelder
The antip Proteinuric and antihypertensive response of verapamil is less than that of the ACE inhibitor trandolapril in patients with non-diabetic renal disease and the antiproteinuric reponse of vera/tran seems to be completely dependent from effective blood pressure reduction.
Clinical interventions in chronic renal failure
1 Citations2000Gerald A. Coles, A. M. El Nahas